Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density

References

• Gao C, Xu Y, Li L, et al. Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai. Chin Med J. 2019;132(14):1749–1751. doi:10.1097/CM9.0000000000000332
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. China Statistical Yearbook. China Statistics Press; 2015.
   Google Scholar
• The Chinese Medical Association of Osteoporosis and Bone Mineral Disease. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin J Osteoporos Bone Miner Res. 2019;25(3):281–309.
   Google Scholar
• Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85(6):1052–1062. doi:10.1111/bcp.13867
   PubMed Web of Science ®Google Scholar
• Haider IT, Simonian N, Saini AS, Leung FM, Edwards WB, Schnitzer TJ. Open-label clinical trial of alendronate after teriparatide therapy in people with spinal cord injury and low bone mineral density. Spinal Cord. 2019;57(10):832–842. doi:10.1038/s41393-019-0303-3
   PubMed Web of Science ®Google Scholar
• Li M, Zhang Z, Xue Q, et al. Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. Arch Osteoporos. 2022;17(1):103. doi:10.1007/s11657-022-01131-8
   PubMed Web of Science ®Google Scholar
• Calvo-Gallego JL, Pivonka P, Ruiz-Lozano R, Martínez-Reina J. Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response. Front Bioeng Biotechnol. 2022;10:940620. doi:10.3389/fbioe.2022.940620
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng H, He JW, et al. Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. Pharmacogenomics J. 2015;15(2):158–164. doi:10.1038/tpj.2014.52
   PubMed Web of Science ®Google Scholar
• Zhou PR, Xu XJ, Zhang ZL, et al. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. Pharmacogenomics. 2015;16(10):1077–1088. doi:10.2217/pgs.15.76
   PubMed Web of Science ®Google Scholar
• Wang JY, Zhou PR, Liu Y, et al. The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women. Pharmacogenomics. 2016;17(3):209–217. doi:10.2217/pgs.15.167
   PubMed Web of Science ®Google Scholar
• Zheng H, Wang C, He JW, Fu WZ, Zhang ZL. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia. Pharmacogenet Genomics. 2016;26(1):12–19. doi:10.1097/FPC.0000000000000181
   PubMed Web of Science ®Google Scholar
• Kafienah WE, Brömme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Int J Exp Pathol. 1998;331(3):727–732.
   Google Scholar
• Dai R, Wu Z, Chu HY, et al. Cathepsin K: the action in and beyond bone. Front Cell Dev Biol. 2020;8:433. doi:10.3389/fcell.2020.00433
   PubMed Web of Science ®Google Scholar
• Troen BR. The regulation of cathepsin K gene expression. Ann N Y Acad Sci. 2006;1068(1):165–172. doi:10.1196/annals.1346.018
   PubMedGoogle Scholar
• Yuan J, Gao YS, Liu DL, et al. PINK1-mediated mitophagy contributes to glucocorticoid-induced cathepsin K production in osteocytes. J Orthop Translat. 2022;38:229–240. doi:10.1016/j.jot.2022.11.003
   PubMed Web of Science ®Google Scholar
• Bonnet N, Douni E, Perréard Lopreno G, Besse M, Biver E, Ferrari S. RANKL-induced increase in Cathepsin K levels restricts cortical expansion in a periostin-dependent fashion: a potential new mechanism of bone fragility. J Bone Miner Res. 2021;36(8):1636–1645. doi:10.1002/jbmr.4307
   PubMed Web of Science ®Google Scholar
• Xiong F, Gao J, Li J, et al. Noncanonical and canonical splice sites: a novel mutation at the rare noncanonical splice-donor cut site (IVS4+1A>G) of SEDL causes variable splicing isoforms in X-linked spondyloepiphyseal dysplasia tarda. Eur J Hum Genet. 2009;17(4):510–516. doi:10.1038/ejhg.2008.219
   PubMed Web of Science ®Google Scholar
• Hung CC, Lee CN, Chang CH, et al. Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Clin Biochem. 2008;41(3):162–166. doi:10.1016/j.clinbiochem.2007.08.014
   PubMed Web of Science ®Google Scholar
• Kannan P, Hadeefa Begum A, Madhana Priya N, et al. Unravelling the Relacatib activity against the CTSK proteins causing pycnodysostosis: a molecular docking and dynamics approach. J Biomol Struct Dyn. 2023;31:1–12. doi:10.1080/07391102.2023.2218927
   Google Scholar
• El-Makawy AI, Ibrahim FM, Mabrouk DM, Abdel-Aziem SH, Sharaf HA, Ramadan MF. Efficiency of turnip bioactive lipids in treating osteoporosis through activation of Osterix and suppression of Cathepsin K and TNF-α signaling in rats. Environ Sci Pollut Res Int. 2020;27(17):20950–20961. doi:10.1007/s11356-020-08540-7
   PubMed Web of Science ®Google Scholar
• Gao G, Zhang ZL, Zhang H, et al. Hip axis length changes in 10,554 males and females and the association with femoral neck fracture. J Clin Densitom. 2008;11(3):360–366. doi:10.1016/j.jocd.2008.04.005
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–1121. doi:10.1016/j.bone.2008.08.106
   PubMed Web of Science ®Google Scholar
• Cummings SR, Santora AC, Black DM, Russell RGG. History of alendronate. Bone. 2020;137:115411. doi:10.1016/j.bone.2020.115411
   PubMed Web of Science ®Google Scholar
• Wang WJ, Fu WZ, He JW, Wang C, Zhang ZL. Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density. Pharmacogenomics J. 2019;19(5):490–498. doi:10.1038/s41397-018-0059-8
   PubMed Web of Science ®Google Scholar
• LaLonde JM, Zhao B, Janson CA, et al. The crystal structure of human procathepsin K. Biochemistry. 1999;38(3):862–869. doi:10.1021/bi9822271
   PubMed Web of Science ®Google Scholar
• Zhu G, Chen W, Tang CY, et al. Knockout and Double Knockout of Cathepsin K and Mmp9 reveals a novel function of Cathepsin K as a regulator of osteoclast gene expression and bone homeostasis. Int J Biol Sci. 2022;18(14):5522–5538. doi:10.7150/ijbs.72211
   PubMed Web of Science ®Google Scholar
• Liu F, Zhou ZF, An Y, et al. Effects of cathepsin K on Emdogain-induced hard tissue formation by human periodontal ligament stem cells. J Tissue Eng Regen Med. 2017;11(10):2922–2934. doi:10.1002/term.2195
   PubMed Web of Science ®Google Scholar
• Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget’s disease. Clin Lab. 2006;52(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Jahn O, Wex T, Klose S, Kropf S, Adolf D, Piatek S. Cathepsin K in treatment monitoring following intravenous zoledronic acid. Biomed Rep. 2014;2(6):915–917. doi:10.3892/br.2014.360
   PubMedGoogle Scholar
• Bautista-Carbajal A, Villanueva-Arriaga RE, Páez-Arenas A, Massó-Rojas F, Frechero Molina N, García-López S. Nitrogen-containing bisphosphonates downregulate Cathepsin K and upregulate annexin V in osteoclasts cultured in vitro. Int J Dent. 2023;2023:2960941. doi:10.1155/2023/2960941
   PubMed Web of Science ®Google Scholar
• Gao LH, Li SS, Yue H, Zhang ZL. Associations of serum Cathepsin K and polymorphisms in CTSK gene with bone mineral density and bone metabolism markers in postmenopausal Chinese women. Front Endocrinol. 2020;11:48. doi:10.3389/fendo.2020.00048
   PubMed Web of Science ®Google Scholar
• Brown JP, Don-Wauchope A, Douville P, Albert C, Vasikaran SD. Current use of bone turnover markers in the management of osteoporosis. Clin Biochem. 2022;109–110:1–10. doi:10.1016/j.clinbiochem.2022.09.002
   PubMed Web of Science ®Google Scholar